I Got Pregnant While on Mounjaro — What Happens Now

What official guidance actually says about tirzepatide and pregnancy

The starting point is the prescribing data, not reassurance. The Mounjaro Summary of Product Characteristics, held on the electronic Medicines Compendium (eMC), states that tirzepatide should not be used during pregnancy. That position is reinforced by NHS England's weight-management guidance, which lists pregnancy, breastfeeding and actively trying to conceive as clear reasons not to use GLP-1 and dual-agonist medicines. The instruction is consistent across every authoritative UK source.

Animal studies in rats and rabbits identified embryo-foetal harm at exposures that produced maternal toxicity, including reduced foetal weight and skeletal variations. Translating animal findings to human risk is never straightforward, and no large-scale human trial data exists specifically for tirzepatide in pregnancy, the clinical programmes that produced the weight-loss evidence deliberately excluded pregnant participants. That absence of human data is itself a reason for caution, not a reason for confidence.

For practical detail on what the SmPC says and how it sits alongside the broader evidence base, the question of whether Mounjaro can be taken in pregnancy is covered in full on a dedicated page. The short answer here remains: it cannot.

Your immediate steps if you have just found out you are pregnant

Stop taking Mounjaro now. Do not wait for your next scheduled injection. Then call your GP surgery or midwifery team as soon as you can, today if the news is fresh. Let them know you have been taking tirzepatide and approximately when your last dose was. They will record it in your notes and decide what monitoring, if any, is appropriate for your pregnancy.

A practical habit that takes under a minute: check the date on your pen and make a note of your last injection day before you call. That one piece of information helps your clinician calculate your wash-out position accurately and assess timing relative to your pregnancy dates. It sounds small, but it makes the conversation more useful immediately.

If you are unsure whether you are pregnant (perhaps you have missed a period or a test is borderline) treat that uncertainty the same way: pause the injection and seek a confirmed answer before continuing. The question of Mounjaro's effect on fertility and conception is explored separately, including the evidence around how weight change and hormonal shifts during treatment may influence menstrual cycles.

Do not restart Mounjaro without a clear conversation with your obstetric team and, when relevant, a prescriber. Restarting postnatally, once you have finished breastfeeding and your clinical team agrees, is a separate decision made in different circumstances entirely.

Contraception, timing and the four-week rule explained

Many people in this situation ask how it happened, given that weight-loss treatment often comes alongside a general push towards better health. The answer often lies in two interacting factors the MHRA has flagged explicitly in its guidance.

First, tirzepatide slows gastric emptying. For women taking an oral contraceptive pill, that slowing can reduce how reliably the pill is absorbed, particularly in the early weeks of treatment and around dose increases. NHS guidance (and the prescribing information that accompanies Mounjaro) advises adding a non-oral contraceptive method, such as condoms, for the first four weeks of treatment and for four weeks after every dose increase. If that advice was not followed, or not clearly communicated at the time of prescribing, the gap is understandable.

Second, meaningful weight loss can restore ovulatory function in women whose cycles had become irregular due to excess weight. Some women discover fertility they had not expected after several weeks on treatment, and if you have found out you got pregnant on Mounjaro, there is dedicated guidance on exactly what to do next. The full picture of Mounjaro during pregnancy covers both of these mechanisms with citations.

Going forward, this contraception advice is relevant both while continuing any GLP-1 treatment in future and during the wash-out period after stopping. The wash-out timeline before trying to conceive should be discussed with your GP, it is not a figure to take from a webpage.

Weight management after pregnancy: planning ahead without rushing

It is worth naming something that does not always get said: discovering you are pregnant while on a weight-loss medicine can bring up complicated feelings, particularly if treatment was going well. Stopping something that was helping is not straightforward emotionally, even when the clinical reason is clear.

Once your pregnancy is complete and you have finished breastfeeding, weight management can be revisited with a clinician. Tirzepatide may be an option again at that point, subject to a fresh clinical assessment. The evidence base for Mounjaro (including the SURMOUNT-1 trial, published in the New England Journal of Medicine, which reported average weight reductions of around 20–21% at the highest dose) does not disappear. It simply waits. Our Mounjaro treatment information page covers how the medicine works and what a private consultation involves.

If you have questions about cost context for when you are ready to return to treatment, the background to the Eli Lilly UK price change is worth reading so you can plan realistically. And if you want to talk to our clinical team about any of this at a stage when treatment is again appropriate, our prescribers are available through the free consultation page. For now, the priority is your GP and midwifery team. That is the right order.